A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients With Active Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2018
At a glance
- Drugs Olamkicept (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors I-MAB Biopharma; Leading Biopharm
- 10 Oct 2018 According to an I-MAB media release, the first patient in mainland China has been dosed at the First Affiliated Hospital of Sun Yat-sen University in Canton, China.
- 31 Aug 2018 Biomarkers information updated
- 29 Dec 2017 Status changed from not yet recruiting to recruiting.